ATE322266T1 - Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten

Info

Publication number
ATE322266T1
ATE322266T1 AT01935373T AT01935373T ATE322266T1 AT E322266 T1 ATE322266 T1 AT E322266T1 AT 01935373 T AT01935373 T AT 01935373T AT 01935373 T AT01935373 T AT 01935373T AT E322266 T1 ATE322266 T1 AT E322266T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
treating cancer
topoisomerase inhibitors
thalidomide
contain
Prior art date
Application number
AT01935373T
Other languages
English (en)
Inventor
Jerome B Zeldis
Andrew Zeitlin
Sol Barer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE322266T1 publication Critical patent/ATE322266T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01935373T 2000-05-15 2001-05-10 Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten ATE322266T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20414300P 2000-05-15 2000-05-15

Publications (1)

Publication Number Publication Date
ATE322266T1 true ATE322266T1 (de) 2006-04-15

Family

ID=22756804

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01935373T ATE322266T1 (de) 2000-05-15 2001-05-10 Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten

Country Status (18)

Country Link
US (2) US7435726B2 (de)
EP (1) EP1307197B1 (de)
JP (1) JP5409981B2 (de)
KR (1) KR100790589B1 (de)
AR (1) AR029084A1 (de)
AT (1) ATE322266T1 (de)
AU (2) AU2001261474B2 (de)
BR (1) BR0110877A (de)
CA (1) CA2408707C (de)
DE (1) DE60118571T2 (de)
DK (1) DK1307197T3 (de)
ES (1) ES2258084T3 (de)
MX (1) MXPA02011218A (de)
NZ (1) NZ522767A (de)
PT (1) PT1307197E (de)
TW (1) TWI289449B (de)
WO (1) WO2001087307A2 (de)
ZA (1) ZA200209638B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression
DE60209471D1 (de) * 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
EP1454626A4 (de) * 2001-12-14 2006-07-19 Sundory Co Ltd Verfahren zur induktion von apoptosis und zusammensetzungen dafür
PL370866A1 (en) * 2002-03-26 2005-05-30 Banyu Pharmaceutical Co, Ltd. Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1705439A (zh) * 2002-04-12 2005-12-07 细胞基因公司 干细胞和祖细胞分化的调节、鉴定及其应用
US7105576B2 (en) * 2002-04-24 2006-09-12 Research Development Foundation Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP2258363A1 (de) * 2002-05-17 2010-12-08 Celgene Corporation Zusammensetzungen zur Behandlung von Krebs
CA2752124A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
TW200501945A (en) 2002-11-06 2005-01-16 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
CA2520997A1 (en) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
US20070270504A1 (en) * 2003-06-20 2007-11-22 Avalon Pharmaceuticals, Inc. Identification of Therapeutic Agents Using Genetic Fingerprinting
US7264819B2 (en) * 2003-06-23 2007-09-04 Anticancer, Inc. Lyase treatment for P. carinii
US20050049299A1 (en) * 2003-08-26 2005-03-03 Aggarwal Bharat B. Selective inhibitors of stat-3 activation and uses thereof
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20060124607A (ko) * 2003-11-06 2006-12-05 셀진 코포레이션 암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
KR20060109979A (ko) * 2003-12-02 2006-10-23 셀진 코포레이션 혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
EP1947094A3 (de) * 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Herstellungsverfahren für Taxanderivate
EP2033638A2 (de) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-Lapachon zur Behandlung von Bauchspeicheldrüsenkrebs
EP2033639A2 (de) * 2004-02-20 2009-03-11 Arqule, Inc. Beta-Lapachon zur Behandlung von Dickdarmkrebs
JP2007523190A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 肺癌の治療のためのβ−ラパコンの使用
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
AU2004319758A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2007536221A (ja) * 2004-05-05 2007-12-13 セルジーン・コーポレーション 骨髄増殖性疾患を治療及び管理するための選択的サイトカイン阻害薬の使用方法及びそれを含む組成物
BRPI0418801A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
ATE502954T1 (de) 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
JPWO2007089043A1 (ja) * 2006-02-03 2009-06-25 武田薬品工業株式会社 リポソーム製剤
WO2007127488A1 (en) * 2006-04-27 2007-11-08 Shenoy Narmada R Compositions and methods for treating or preventing diseases of body passageways
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2014651A1 (de) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Verbindungen und Verfahren zur Modulierung von Rho-GTPasen
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
EP2211870A1 (de) * 2007-11-01 2010-08-04 Celgene Corporation Cytidinanaloga zur behandlung von myelodysplastischem syndrom
WO2009067706A1 (en) * 2007-11-21 2009-05-28 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
US20120059026A1 (en) * 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2014180882A2 (en) * 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
HUE065109T2 (hu) 2015-06-26 2024-05-28 Celgene Corp Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
WO2017147316A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
KR101945492B1 (ko) * 2016-04-29 2019-02-08 (주)나디안바이오 나프토퀴논계 화합물을 유효성분으로 포함하는 항암제 치료 관련 부작용으로 나타나는 피로, 악액질, 통증, 인지능력 저하 및 조혈줄기세포 감소의 예방 또는 개선용 조성물
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
KR101851470B1 (ko) 2016-12-19 2018-06-11 한림대학교 산학협력단 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
GB9523493D0 (en) * 1995-11-16 1996-01-17 British Biotech Pharm Preparation of allyl succinate derivatives and starting materials therefore

Also Published As

Publication number Publication date
HK1054502A1 (en) 2003-12-05
AU2001261474B2 (en) 2006-03-09
ES2258084T3 (es) 2006-08-16
DE60118571D1 (de) 2006-05-18
EP1307197B1 (de) 2006-04-05
TWI289449B (en) 2007-11-11
US20050148524A1 (en) 2005-07-07
KR100790589B1 (ko) 2008-01-02
PT1307197E (pt) 2006-08-31
MXPA02011218A (es) 2004-08-19
CA2408707C (en) 2010-04-13
NZ522767A (en) 2004-07-30
JP5409981B2 (ja) 2014-02-05
EP1307197A2 (de) 2003-05-07
US7435726B2 (en) 2008-10-14
DE60118571T2 (de) 2007-02-01
US20020035090A1 (en) 2002-03-21
CA2408707A1 (en) 2001-11-22
WO2001087307A2 (en) 2001-11-22
KR20030025922A (ko) 2003-03-29
AU6147401A (en) 2001-11-26
ZA200209638B (en) 2003-11-27
WO2001087307A3 (en) 2002-07-25
AR029084A1 (es) 2003-06-04
JP2003533484A (ja) 2003-11-11
DK1307197T3 (da) 2006-07-03
BR0110877A (pt) 2003-03-11

Similar Documents

Publication Publication Date Title
ATE322266T1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ATE341341T1 (de) Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
CY2022009I1 (el) Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
EP1565230A4 (de) Materialzusammensetzungen und verwandtesysteme und verfahren zur behandlung von herzerkrankungen
EP1469871A4 (de) Verfahren zur behandlung von apoptose und zusammensetzungen dafür
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
EP1633362A4 (de) Verbindungen, verfahren und pharmazeutische zusammensetzungen zur hemmung von parp
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
IL230815A0 (en) Dictopiperazine compounds and pharmaceutical preparations containing them for the treatment of T-cell mediated diseases
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
DE60011570D1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
PT1048211E (pt) Tratamento fitossanitario de plantas e composicoes utilizaveis para este efeito
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE413171T1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz- superinfektionen und pilz-rezidiven
ATE274044T1 (de) Zusammensetzungen zur behandlung von gewebe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1307197

Country of ref document: EP